Comparative in vivo antiangiogenic effects of calreticulin from Trypanosoma cruzi and Homo sapiens sapiens

Angiogenesis is a complex multi-step process of neovascularization arising from preexisting blood vessels whose generation is regulated by pro- and anti-angiogenic factors. Both Trypanosoma cruzi calreticulin (TcCRT) and its human counterpart (HuCRT) are antiangiogenic. This is the first report wher...

Full description

Saved in:
Bibliographic Details
Published in:Biological research 2010, Vol.43 (3), p.287-289
Main Authors: Toledo, Victor, Ramírez, Galia, Valck, Carolina, López, Nandy, Ribeiro, Carolina H, Maldonado, Ismael, Aguilar, Lorena, Lemus, David, Ferreira, Arturo
Format: Article
Language:English
Subjects:
Angiogenesis Inhibitors - isolation & purification
Angiogenesis Inhibitors - pharmacology
Animals
anti-angiogenesis
BIOLOGY
Calreticulin
Calreticulin - isolation & purification
Calreticulin - pharmacology
Chick Embryo
Humans
Neovascularization, Pathologic
T. cruzi
Trypanosoma cruzi - chemistry
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Angiogenesis is a complex multi-step process of neovascularization arising from preexisting blood vessels whose generation is regulated by pro- and anti-angiogenic factors. Both Trypanosoma cruzi calreticulin (TcCRT) and its human counterpart (HuCRT) are antiangiogenic. This is the first report where the TcCRT and HuCRT anti-angiogenic properties are compared in vivo. In the chick embryonic chorioallantoid membrane assay (CAM) and at equimolar concentrations, TcCRT displayed significantly higher antiangiogenic activities than its human counterpart. LPS had marginal effects at the concentrations present in the recombinant protein preparations and the TcCRT antiangiogenic effects were largely inhibited by specific polyclonal antibodies, thus, reinforcing the fact that the observed TcCRT effects can be attributed to the parasite-derived molecule and not to the endotoxin. The antiangiogenic TcCRT effects correlate with its anti-tumor in vivo effects, as recently shown in our laboratory.
ISSN:0716-9760
0717-6287
DOI:10.4067/S0716-97602010000300004